PD-L1 receptors are upregulated in multiple tumor cell types in response to proinflammatory cytokines (e.g., IFN-γ) so that they can inhibit activated TILs via PD-1/PD-L1 interaction.102. This evidence concerns the gene PDCD1 and neoplasm.